← Back to Search

Alpha-2 Adrenergic Agonist

Low-Dose Clonidine for PTSD

Phase 3
Recruiting
Led By Mindy R Waite, PhD, MS
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥18 years old
Currently has PTSD diagnosis as determined by clinical diagnosing
Must not have
Currently receiving exposure therapy
Urgent hypertension (BP above 160/100) or symptomatic of hypertension (having a hypertensive emergency)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6 of current phase
Awards & highlights
Pivotal Trial

Summary

This trial is testing whether the drug clonidine can help improve symptoms of PTSD in veterans. It will look at daytime, nighttime, and sleep-related behaviors.

Who is the study for?
This trial is for US military veterans over 18 with PTSD, who have specific scores on the PCL5 and CAPS assessments indicating intrusion or nightmares. Participants must speak English and be willing to visit the clinic as required. Excluded are those with certain heart conditions, severe hypertension, kidney disease, recent heart attack or stroke, drug use disorders, other mental health issues that could interfere with participation, or those taking conflicting medications.
What is being tested?
The study tests if low-dose clonidine can improve PTSD symptoms in veterans compared to a placebo. The hypothesis suggests benefits in daytime behavior and sleep-related issues. Participants will receive either clonidine pills or a placebo without knowing which one they're getting.
What are the potential side effects?
Clonidine may cause side effects like dizziness, dry mouth, fatigue, headache and potentially low blood pressure. It's important for participants to report any discomfort they experience during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with PTSD by a healthcare professional.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with PTSD by a healthcare professional.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently undergoing exposure therapy.
Select...
My blood pressure is above 160/100 or I am experiencing a hypertensive emergency.
Select...
My blood pressure is below 100/60 or I experience symptoms like dizziness.
Select...
I have a history of slow heartbeats.
Select...
I have a history of pheochromocytoma.
Select...
I have a history of Raynaud's phenomenon.
Select...
My kidney disease is in stage 5.
Select...
I have not used any unprescribed drugs or misused prescribed ones in the last 30 days.
Select...
I am taking pain medication other than opiates.
Select...
I am not taking any barbiturate medications.
Select...
I am not taking sedatives, sleeping pills, or tranquilizers.
Select...
I have sleep apnea and do not follow my treatment plan.
Select...
I have been prescribed clonidine in the last 6 months.
Select...
I am taking an α2 agonist medication.
Select...
I am taking medication for high blood pressure or prostate issues.
Select...
I am currently taking or have taken opiates like buprenorphine, hydrocodone, or oxycodone.
Select...
I am taking antipsychotic medication.
Select...
I am currently taking benzodiazepines.
Select...
I am taking Cyproheptadine.
Select...
I have a legal guardian.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6 of current phase
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6 of current phase for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) questions B2 and E6 at 6 weeks into phase
Change from Baseline in PTSD Checklist-Military Version (PCL-5) at 6 weeks into phase
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) at 6 weeks into phase
Secondary study objectives
Change from Baseline in Patient Health Questionnaire (PHQ9) at 6 weeks into phase
Change from Baseline in Sleep Diary at 6 weeks into phase
Change from Baseline in quality of life scale (Q-LES-Q-SF) at 6 weeks into phase

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Clonidine PhaseExperimental Treatment1 Intervention
Participants will receive clonidine titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.
Group II: Placebo PhasePlacebo Group1 Intervention
Participants will receive placebo titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,401 Previous Clinical Trials
2,460,273 Total Patients Enrolled
Aurora Health CareLead Sponsor
45 Previous Clinical Trials
16,386 Total Patients Enrolled
Mindy R Waite, PhD, MSPrincipal InvestigatorAdvocate Aurora Health
Gregory Burek, MD, MSPrincipal InvestigatorWake Forest University Health Sciences
Michael Fendrich, PhDPrincipal InvestigatorWake Forest University Health Sciences
4 Previous Clinical Trials
1,279 Total Patients Enrolled

Media Library

Clonidine (Alpha-2 Adrenergic Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT04877093 — Phase 3
Post-Traumatic Stress Disorder Research Study Groups: Clonidine Phase, Placebo Phase
Post-Traumatic Stress Disorder Clinical Trial 2023: Clonidine Highlights & Side Effects. Trial Name: NCT04877093 — Phase 3
Clonidine (Alpha-2 Adrenergic Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04877093 — Phase 3
~5 spots leftby Mar 2025